This week, Shawn Wilkie and Dr. Ivan Zak welcome Todd Zion, the Founder and CEO of Akston, a biotechnology company pioneering a new class of long-acting therapeutics for companion animals. Todd, who previously founded a company that engineered the first clinically tested glucose-responsive insulin, explains why his pivot from a $500M human health exit to the pet health market makes perfect sense. Todd details how Akston's Ambifect platform is being used to develop treatments for chronic pain, dermatitis, and cancer that can last for six months or even a year on a single dose, reducing the burden on pet owners and veterinary teams. He also provides a candid look at the streamlined regulatory pathways in veterinary medicine compared to human health, and how their manufacturing platform is poised to make these cutting-edge biologics more accessible and cost-effective for everyday pet care. Learn more about Akston. Todd recommends "Zoobiquity: The Astonishing Connection Between Human and Animal Health" by Barbara Natterson-Horowitz, Kathryn Bowers.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related